NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
Rhea-AI Summary
NanoViricides (NYSE: NNVC), a clinical-stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Company President & Executive Chairman Anil R. Diwan will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NNVC declined 3.65%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Anil R. Diwan, President & Executive Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About NanoViricides
The Company has developed a novel broad-spectrum antiviral drug, NV-387, that can treat many unrelated viral infections and could be as revolutionary as the development of penicillin to treat many bacterial infections. NV-387, has completed Phase I human clinical trial successfully. The Company is preparing an application for a Phase II human efficacy clinical trial of NV-387 for the treatment of MPox in African region. Additional clinical trials for RSV, Influenza, COVID and other respiratory infections are planned. NV-387 is expected to be active for treatment of Measles virus infection as well. Additionally, the Company has developed NV-HHV-1, a drug for treatment of almost all herpesvirus infections, and NV-HIV-1 for treatment of HIV/AIDS. The Company's technology uniquely enables drugs that the virus cannot escape from, despite constant changes in the virus that have stymied traditional antibodies vaccines and small therapeutics approaches. The overall market size for the above three products alone is in the range of
About D. Boral Capital
D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.
D. Boral Capital is a leader on Wall Street, having aggregated over
For further information:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
Source NanoViricides, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250560
FAQ
What is the purpose of NanoViricides (NNVC) participating in the D. Boral Capital Conference 2025?
When and where is NanoViricides (NNVC) presenting at the D. Boral Capital Conference?
Who will represent NanoViricides (NNVC) at the D. Boral Capital Conference 2025?
How can investors schedule meetings with NanoViricides (NNVC) management at the conference?
